Indaptus Therapeutics Inc... (INDP)
0.87
-0.03 (-3.33%)
At close: Jan 15, 2025, 10:36 AM
undefined% (undefined)
| Bid | 0.87 |
| Market Cap | 10.45M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.88 |
| Volume | 18,832 |
| Avg. Volume (20D) | 117,757 |
| Open | 0.88 |
| Previous Close | 0.90 |
| Day's Range | 0.86 - 0.90 |
| 52-Week Range | 0.81 - 3.10 |
| Beta | undefined |
About INDP
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2015
Employees 7
Stock Exchange NASDAQ
Ticker Symbol INDP
Website https://indaptusrx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for INDP stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 877.01% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
-4.76%
Indaptus Therapeutics shares are trading lower. Th...
Unlock content with
Pro Subscription
3 months ago ·
Source
+12.6%
Indaptus Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.
